Amgen Middle East Regulatory Director On Regulatory Expertise And Drug Pricing - An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Amgen is targeting the Middle East as a new growth area, and it plans to venture further into Gulf countries from Saudi Arabia and war-torn Iraq to countries like Algeria and Libya.
You may also be interested in...
Amgen Middle East Regulatory Affairs Director Adel Djalal On Drug Pricing And Regulatory Environment - An Interview With PharmAsia News (Part 2 of 2)
Amgen is targeting the Middle East as a new growth area, and it plans to venture further into Gulf countries, from Saudi Arabia and war-torn Iraq to countries like Algeria and Libya.
Amgen Middle East Regulatory Affairs Director Adel Djalal On Drug Pricing And Regulatory Environment - An Interview With PharmAsia News (Part 2 of 2)
Amgen is targeting the Middle East as a new growth area, and it plans to venture further into Gulf countries, from Saudi Arabia and war-torn Iraq to countries like Algeria and Libya.
Can Emerging Markets Fuel Growth And Restore Trust In Pharma?
When looking at emerging markets, most biopharma analysts focus on commercial opportunities - whether "pharmerging" markets will help mitigate lost sales in the U.S. and Europe stemming from the patent cliff, increasing pressure from payers and related challenges